Aethlon Medical Corp (AEMD): יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Aethlon Medical (AEMD) is protected by exclusive patents for blood purification of tumor markers and viruses under strict FDA control. The EV/EBITDA metric on GURU.Markets, which stands at 0.00, confirms the business status. While a team of talented engineers is dedicated to the mission of saving lives, the costs of clinical trials are depleting capital, forcing the company to attract new investors.

This indicator correlates the total enterprise value, including net debt, with operating profit, allowing for an assessment of capital protection against excessive leverage. For Aethlon Medical (AEMD), which is currently in the clinical trial stage for the Hemopurifier and has no current revenue, this metric reflects the cost of awaiting FDA approval. Analyzing the EV/EBITDA value for Aethlon Medical (AEMD) helps determine the depth of the valuation drawdown and balance the risk of missed profits with a conservative approach to capital.